These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 4555002)

  • 21. [Modalities of treatment of Parkinsonian syndrome with L-dopa].
    Yanniotis G; Eisenring JJ; Gauthier G; Tissot R; de Ajuriaguerra J
    Int J Neurol; 1972; 9(1):23-32. PubMed ID: 5086635
    [No Abstract]   [Full Text] [Related]  

  • 22. [Efficacy and side effects of L-dopa in patients with Parkinson's syndrome].
    Lombardo L
    Arch Invest Med (Mex); 1973; 4(3):215-24. PubMed ID: 4784173
    [No Abstract]   [Full Text] [Related]  

  • 23. Experimental evaluation of L-dopa penetration in brain.
    De la Torre JC; Mullan S
    Trans Am Neurol Assoc; 1971; 96():227-9. PubMed ID: 5159088
    [No Abstract]   [Full Text] [Related]  

  • 24. Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486).
    Yahr MD; Duvoisin RC; Mendoza MR; Schear MJ; Barrett RE
    Trans Am Neurol Assoc; 1971; 96():55-8. PubMed ID: 5159129
    [No Abstract]   [Full Text] [Related]  

  • 25. [Clinical experience with L-DOPA in the treatment of parkinsonism].
    Chiba T
    No To Shinkei; 1970 Dec; 22(12):1399-405. PubMed ID: 5536833
    [No Abstract]   [Full Text] [Related]  

  • 26. [L-DOPA-and dopa-decarboxylase inhibitor combination for the treatment of Parkinsonism].
    Fujimori N; Kito S; Yamamoto M; Itoga E; Kosaka K
    Nihon Rinsho; 1974 Mar; 32(3):579-86. PubMed ID: 4859014
    [No Abstract]   [Full Text] [Related]  

  • 27. L-dopa therapy in parkinsonism: mechanism of action.
    Sandler M
    Psychiatr Neurol Neurochir; 1971; 74(4):331-3. PubMed ID: 5146239
    [No Abstract]   [Full Text] [Related]  

  • 28. [L-dopa treatment of parkinsonism].
    Szulc-Kuberska J; Niewodniczy A; Poźniak-Patewicz E; Wolczyk-Orzechowska M
    Neurol Neurochir Pol; 1973; 7(1):63-8. PubMed ID: 4511385
    [No Abstract]   [Full Text] [Related]  

  • 29. [Effect of the combined treatment of Parkinson patients with L-Dopa and a decarboxylase inhibitor (Ro4-4602). Quantitative analysis of bradykinesia by means of reaction time measurements].
    Kaufmann W; Butz P; Wiesendanger M
    Dtsch Z Nervenheilkd; 1970; 197(1):85-100. PubMed ID: 5522871
    [No Abstract]   [Full Text] [Related]  

  • 30. [Therapy of Parkinson's syndrome with L-dopa only and in combination with a decarboxylase inhibitor. A comparison].
    Feise G; Paal G
    Nervenarzt; 1974 Mar; 45(3):126-32. PubMed ID: 4832035
    [No Abstract]   [Full Text] [Related]  

  • 31. [Clinical effect of L-DOPA and electromyographic study of Parkinsonism].
    Sato G; Ito H; Handa Y; Takahashi I; Iijima K
    No To Shinkei; 1971 Mar; 23(3):325-32. PubMed ID: 5107821
    [No Abstract]   [Full Text] [Related]  

  • 32. [Treatment of Parkinsonic syndrome with levo-Dopa. Case reports].
    Rosati G; Agnetti V; Mura F; Granieri E
    Minerva Med; 1974 May; 65(33):1811-23. PubMed ID: 4602058
    [No Abstract]   [Full Text] [Related]  

  • 33. [L-DOPA with the decarboxylase inhibitor Ro 4-4602 in the treatment of Parkinson's disease].
    Lakke JP; Nienhuis RJ; Meyer R; Zwols F; Schut T
    Ned Tijdschr Geneeskd; 1972 Nov; 116(48):2180-4. PubMed ID: 4639072
    [No Abstract]   [Full Text] [Related]  

  • 34. Mood changes during l-dopa therapy.
    Anumonye A
    J Med Soc N J; 1972 Feb; 69(2):139-43. PubMed ID: 4550284
    [No Abstract]   [Full Text] [Related]  

  • 35. [Disulfiram and L-dopa in patients with Parkinson's syndrome and in torsion dystonia].
    Serrano PA; Irigoyen M
    Prensa Med Mex; 1972; 37(7):246-50. PubMed ID: 4646433
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of Parkinson's disease with L-DOPA and an association L-DOPA plus a DOPA decarboxylase inhibitor.
    Fazio C; Agnoli A; Casacchia M; Reitano M; Ruggieri S; Barba C; Volante F
    Z Neurol; 1972; 202(4):347-55. PubMed ID: 4117654
    [No Abstract]   [Full Text] [Related]  

  • 37. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; de Ajuriaguerra J
    Presse Med (1893); 1969 Apr; 77(17):619-22. PubMed ID: 5785081
    [No Abstract]   [Full Text] [Related]  

  • 38. Quantitative effects of L-dopa on different types of movements and muscle tone in Parkinsonian patients.
    Knutsson E; Mårtensson A
    Scand J Rehabil Med; 1971; 3(3):121-30. PubMed ID: 5156174
    [No Abstract]   [Full Text] [Related]  

  • 39. [Treatment of Parkinson's syndrome with L-dopa].
    Kaeser HE; Ferel D; Wurmser P
    Schweiz Med Wochenschr; 1970 May; 100(19):805-13. PubMed ID: 4924276
    [No Abstract]   [Full Text] [Related]  

  • 40. [Personal experience in the treatment of Parkinson's disease with L-Dopa].
    Figuerido JA; De la Herrán J
    Rev Clin Esp; 1970 Dec; 119(6):555-62. PubMed ID: 5509794
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.